Bone Biologics Corporation (BBLG) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.61 |
| Open | 0.62 |
| Day High | 0.63 |
| Day Low | 0.59 |
| 52-Week High | 4.13 |
| 52-Week Low | 0.59 |
| Volume | 83,380 |
| Average Volume | 334,250 |
| Market Cap | 1.13M |
| PE | -0.28 |
| EPS | -2.27 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 1.36 |
| Change | 0.02 |
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
GlobeNewswire Inc.
Dec 23, 2025 1:00 PM GMT
Milestone advances manufacturing readiness and supports long-term commercialization strategyBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of or